Urticaria News

News

Promising treatment options for chronic hives on the horizon

Jairia Dela Cruz, 20230328140000

Dupilumab, barzolvolimab, and remibrutinib appear to help reduce disease activity in patients with chronic spontaneous urticaria, according to the results of three studies presented at AAAAI 2023.

Lirentelimab shows promise in treatment-resistant chronic urticaria

20220514090000

In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.

Ligelizumab improves symptoms, QoL in patients with urticaria

Audrey Abella, 20220302100000

In patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite treatment, the monoclonal anti-immunoglobulin E antibody ligelizumab improved symptom control regardless of BHRA* status, as well as dermatology quality of life (QoL) regardless of angioedema status, findings from a phase IIb study have shown.

Cetirizine an attractive alternative to diphenhydramine for hives

Jairia Dela Cruz, 20200721150000

Cetirizine drip for treating acute urticaria is as effective as intravenous diphenhydramine, with the added benefits of less sedation, fewer adverse events, shorter treatment time, and lower rates of revisit to treatment centre, according to the results of a phase III study.

Original New Drug Application Approvals by US FDA (01 - 15 October 2019)

20191015000000

New drug applications approved by US FDA as of 01 - 15 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

20181101020000

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Rupatadine safe, effective for treating chronic spontaneous urticaria

20180820060000

Rupatadine effectively relieves pruritus in patients with chronic spontaneous urticaria and is well tolerated without serious or clinically significant adverse effects, according to the results of a phase III trial.

Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018

Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018

DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.

Product Highlight - RELIZEMA

16 Jun 2021

Furfuryl Palmitate

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.